Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atiprimod in Refractory or Relapsed Multiple Myeloma
NCT00086216Phase 2Completed
- Sponsor
- Callisto Pharmaceuticals, Inc.
- Start
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atiprimod in multiple myeloma (MM), sponsored by Callisto Pharmaceuticals, Inc.. Started May 2004; status: completed.
02
Drugs
atiprimod
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00086216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086216.